IBRX vs. IOVA, TGTX, SANA, HRMY, NBIX, TECH, QGEN, RGEN, PCVX, and RVMD
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Iovance Biotherapeutics (IOVA), TG Therapeutics (TGTX), Sana Biotechnology (SANA), Harmony Biosciences (HRMY), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector.
ImmunityBio (NASDAQ:IBRX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings.
Iovance Biotherapeutics has a net margin of -23,615.70% compared to ImmunityBio's net margin of -198,994.05%. ImmunityBio's return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.
8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 83.4% of ImmunityBio shares are owned by company insiders. Comparatively, 10.4% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ImmunityBio has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.
In the previous week, Iovance Biotherapeutics had 5 more articles in the media than ImmunityBio. MarketBeat recorded 8 mentions for Iovance Biotherapeutics and 3 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.23 beat Iovance Biotherapeutics' score of 0.69 indicating that ImmunityBio is being referred to more favorably in the media.
ImmunityBio presently has a consensus target price of $6.00, indicating a potential downside of 6.54%. Iovance Biotherapeutics has a consensus target price of $24.64, indicating a potential upside of 177.44%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than ImmunityBio.
Iovance Biotherapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Iovance Biotherapeutics received 557 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 74.57% of users gave Iovance Biotherapeutics an outperform vote while only 13.04% of users gave ImmunityBio an outperform vote.
Summary
Iovance Biotherapeutics beats ImmunityBio on 12 of the 18 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
